Vertex’s pain drug succeeds in late-stage studies, marking major breakthrough in search for new, non-opioid medicines
An experimental non-opioid drug lowered pain levels in a series of pivotal studies, according to the drug’s developer Vertex Pharmaceuticals, which means a new, non-addictive type of pain medicine could soon be on the market.
In two Phase III studies that each had over 1,000 participants, those who received Vertex’s pain pill VX-548 after surgery experienced a greater reduction in pain over two days compared to those who received placebo. Participants in one study had an abdominoplasty, known otherwise as a tummy tuck, and those in the second had bunion surgery.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
